Palisade Bio at Morgan Stanley conference: broadens ibd push

Palisade Bio said its $125 million cash balance will fund parallel Phase II trials of PALI-2108 in ulcerative colitis and Crohn’s disease through completion by the end of 2027, with an additional six to nine months of runway. The company expects ulcerative-colitis patient screening within weeks, Crohn’s IND clearance in H2 2026, and first Crohn’s dosing in Q1 2027. Early open-label Phase I results showed 100% response and 40% remission in ulcerative colitis, plus 40% response/remission in Crohn’s, but these small uncontrolled data require confirmation in randomized studies amid a crowded IBD market.

Analysis

PALI’s valuation is effectively an option on a differentiated tolerability profile, not on the small, uncontrolled efficacy dataset. The relevant benchmark is whether randomized UC remission clears placebo by enough to justify displacement of established oral agents; a statistically positive but commercially modest result would likely not support a premium strategic valuation. The reported trial-dose inconsistency in management’s discussion also raises execution/governance questions that should be resolved in the registry before underwriting the program.

Near term, site activation and first-patient dosing are sentiment catalysts but do not materially de-risk efficacy. Over the next 1-3 months, the key diligence item is the ClinicalTrials.gov posting: final dose arms, enrollment target, baseline disease severity, rescue rules, and endpoint definitions will determine whether the stated power translates into a credible readout. The parallel-program strategy raises operating leverage but also concentrates burn and makes an equity raise probable well before the nominal runway endpoint; biotech financings are typically priced off positive enrollment/PK headlines rather than cash necessity.

The contrarian view is that gut-local exposure may be valuable only if it produces a clearly superior discontinuation rate. If systemic exposure is lower, efficacy can also be capped in deeper Crohn’s disease, where management is escalating dose and using an open-label design; interim Crohn’s updates would therefore be weak evidence and potentially promotional. Competitive read-through is limited for MRK and other large pharma until controlled efficacy and safety establish a credible licensing asset.

There is no clean liquid pair trade among the supplied tickers. PALI is suitable only as a small, catalyst-driven long after registry confirmation, with sizing reflecting binary clinical, financing, and microcap liquidity risk rather than the stated cash balance.

Key Decisions for Investors

• Do not chase PALI on conference-driven strength. Set a watch trigger for the UC registry posting within the next month; initiate only if the final design preserves a placebo-controlled 12-week remission endpoint, clearly specified dose arms, and enrollment consistent with the claimed power.
• For a speculative 6-12 month position, cap PALI at venture-style sizing (25-50 bps NAV initially). Add only after early enrollment pace demonstrates the activated-site footprint is translating into recruitment; target 2-3x upside requires credible controlled efficacy, while dilution or slow enrollment can impair equity value by 30-50% before data.
• Treat any Crohn’s interim efficacy disclosure in 1H27 as non-confirmatory because the planned study is open label. Use it as a liquidity event to trim rather than as a reason to increase exposure unless paired with objective endoscopic, biomarker, and discontinuation data against a pre-specified benchmark.
• Falsify the constructive thesis if the registry reveals lower-than-expected statistical rigor, meaningful enrollment delays, gastrointestinal discontinuations inconsistent with the tolerability claim, or a financing completed at a material discount before enrollment is established. In those cases, avoid PALI until post-financing price discovery.